Huya Bioscience International expands into South Korea

3 December 2015

Chinese pharma company Huya Bioscience International said it has opened its first corporate office in South Korea, in line with its strategy to accelerate drug development by aiding local firms initiate clinical trials and gain approval for new compounds.

Huya was the first company to leverage the Tripartite Cooperation Treaty between Korea, China and Japan to advance product development in Japan based on Chinese data.

The recent signing of an agreement between Huya and the Korean Drug Development Fund (KDDF) will enable Huya and the KDDF to form partnerships with local companies and research institutions to accelerate the development and commercialization of Korean pharmaceutical discoveries for the global markets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK